• Lapatinib 250mg

Lapatinib 250mg

SKU:52048

Lapatinib is used with capecitabine for HER2-positive breast cancer that is advanced or has spread after earlier HER2-directed treatment.

It can also be used with letrozole for postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer when hormone treatment is appropriate.

Usual adult dose range: 1,250 mg to 1,500 mg once daily, depending on the breast cancer combination treatment being used.


Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.


  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.